Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1509026
This article is part of the Research Topic Advancing NSCLC Treatment: Overcoming Challenges in Immune Checkpoint Inhibitor Therapy View all articles

Pulmonary Enteric Adenocarcinoma with Progression Disease After Second -line Therapy: A Case Report

Provisionally accepted
Ya Guo Ya Guo Bin Zhang Bin Zhang Heng Zhang Heng Zhang Yunbin Gao Yunbin Gao Haibo Zhao Haibo Zhao Pei Jiang Pei Jiang Qing-Qing Yu Qing-Qing Yu *
  • Jining First People's Hospital, Jining, China

The final, formatted version of the article will be published soon.

    Pulmonary enteric adenocarcinoma (PEAC, also known as Enteric-type adenocarcinoma of the lung, lung -ETAC) is a rare subtype of non-small cell lung cancer (NSCLC) that has the same morphological and immunohistochemical characteristics as colorectal adenocarcinoma and requires gastroenteroscopy to rule out lesions of enteric origin. As a rare solid tumor in lung cancer, PEAC has unique clinical outcome, imaging, pathological and molecular characteristics, and poor prognosis. However, the molecular characteristics and therapeutic biomarkers of PEAC are unclear, and its treatment remains challenging. In this case, we describe a 61-yearold man diagnosed with advanced primary PEAC with KRAS mutation. In the case of unknown PD-L1 expression status, first-line treatment was given to lung adenocarcinoma regimen (immunotherapy combined with chemotherapy), progression occurred after 2 cycles, and progression-free survival (PFS) was 1.5 months. Then the second-line XELOX regimen (oxaliplatin combined with capecitabine) was adjusted. The lesions were significantly reduced after 2 and 4 cycles, and the disease progressed again after 6 cycles, with a PFS of 4.5 months.Anlotinib targeted drugs were selected for third-line treatment, but considering the overall poor condition of the patient, the patient himself refused further treatment. Finally, after discharge, the patient went to the local hospital for nutritional support and symptomatic treatment. The results suggest that standard first-line therapies (immunotherapy plus chemotherapy) and colorectal cancer regimens may have a relatively limited impact on survival in KRAS-driver positive advanced PEAC.

    Keywords: Pulmonary enteric adenocarcinoma, Non-small cell lung cancer, diagnosis, Treatment, prognosis

    Received: 10 Oct 2024; Accepted: 02 Jan 2025.

    Copyright: © 2025 Guo, Zhang, Zhang, Gao, Zhao, Jiang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qing-Qing Yu, Jining First People's Hospital, Jining, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.